Pure Global AI
NCT05930275Not yet recruiting

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

A Multi-Country, Prospective, Post-Marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3-years in Real-World Clinical Practice (UPlift)
AbbVieClinicalTrials.gov
Verified
Study focus
Disease/Condition
Crohn's Disease
Study type
Observational
Sponsor & location
Primary sponsor
AbbVie
Timeline & enrollment
Phase
N/A
Start date
Aug 15, 2023
End date
Sep 30, 2028
Enrollment
1200 participants
Primary outcome

Time to Achieve First Clinical Response (CR) per Patient-Reported Outcome 2 (PRO2) (Daily CR-PRO),Percentage of Participants Achieving Clinical Remission per Harvey Bradshaw Index (HBI) Among those with Clinical Response-Harvey Bradshaw Index (CR-HBI) at End of Induction Therapy

Summary

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal
 tract. This study will assess how safe and effective upadacitinib is in treating moderately
 to severely active CD in real world. Speed of onset and durability of effectiveness will be
 assessed.
 
 Upadacitinib is a drug approved for the treatment of CD. All study participants will receive
 upadacitinib as prescribed by their study doctor in accordance with approved local label.
 Approximately 1200 participants will be enrolled in approximately 230 sites across the world.
 
 Participants will receive upadacitinib as prescribed by their physician according to their
 routine clinical practice and local label. Participants will be followed for up to 3 years.
 
 There is expected to be no additional burden for participants in this trial. Study visits may
 be conducted on-site or virtually as per standard of care.

ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease [regional enteritis]Crohn disease of small intestine
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05930275
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05930275 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Crohn's Disease. Target enrollment is 1200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.